ArticleJournal of medicinal chemistry2010
Almiramides A-C: discovery and development of a new class of leishmaniasis lead compounds.
Article in Journal of medicinal chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 119 citations in OpenAlex.
- Structure of a putative terminal amidation domain in natural product biosynthesis.Structure (London, England : 1993) · 2025Article
- Therapeutical Potential and Immunomodulatory Profile ofACS infectious diseases · 2025Article
- The Cyanobacterial Oxadiazine Nocuolin A Shows Broad-Spectrum Toxicity Against Protozoans and the Nematode C. elegans.Microbial ecology · 2025Article
- Chemical diversity of cyanobacterial natural products.Natural product reports · 2025Review
- Marine Natural Products as Novel Treatments for Parasitic Diseases.Handbook of experimental pharmacology · 2025Review
- Marine Cyanobacteria: A Rich Source of Structurally Unique Anti-Infectives for Drug Development.Molecules (Basel, Switzerland) · 2024Review
- A Review of the Antimicrobial Properties of Cyanobacterial Natural Products.Molecules (Basel, Switzerland) · 2023Review
- Anti-Infective Secondary Metabolites of the Marine CyanobacteriumMarine drugs · 2022Review
- Anti-leishmanial compounds from microbial metabolites: a promising source.Applied microbiology and biotechnology · 2021Review
- Bioprospecting marine actinomycetes for antileishmanial drugs: current perspectives and future prospects.Heliyon · 2021Review
- Influence ofMolecules (Basel, Switzerland) · 2021Article
- Cyanobacteria-From the Oceans to the Potential Biotechnological and Biomedical Applications.Marine drugs · 2021Review
- Microorganisms as a Potential Source of Molecules to Control Trypanosomatid Diseases.Molecules (Basel, Switzerland) · 2021Review
- Marine Cyanobacteria: A Source of Lead Compounds and their Clinically-Relevant Molecular Targets.Molecules (Basel, Switzerland) · 2020Review
- Design, Synthesis and Biological Evaluation of Jahanyne Analogs as Cell Cycle Arrest Inducers.Marine drugs · 2020Article
- Dereplication of microbial metabolites through database search of mass spectra.Nature communications · 2018Article
- New Peptides Isolated from Marine Cyanobacteria, an Overview over the Past Decade.Marine drugs · 2017Review
- Alkynyl-Containing Peptides of Marine Origin: A Review.Marine drugs · 2016Review
- Genome-Directed Lead Discovery: Biosynthesis, Structure Elucidation, and Biological Evaluation of Two Families of Polyene Macrolactams against Trypanosoma brucei.ACS chemical biology · 2015Article
- Biological targets and mechanisms of action of natural products from marine cyanobacteria.Natural product reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Leishmaniasis is a debilitating disease caused by protozoan parasites of the genus Leishmania, which affects an estimated 12 million people worldwide. The discovery of new lead compounds for leishmaniasis is therefore a pressing concern for global health programs. The organic extract of a Panamanian collection of the marine cyanobacterium Lyngbya majuscula showed strong in vitro activity in two complementary screens against the tropical parasite Leishmania donovani, the causative agent of visceral leishmaniasis. Chromatographic separation of this complex mixture led to the isolation of the highly N-methylated linear lipopeptides, almiramides A-C (1-3). Comparison with the biological activities of a number of related metabolites and semisynthetic derivatives revealed key features required for activity and afforded one new compound (11) with superior in vitro activity. Subsequent synthesis of a library of simplified analogues led to the discovery of several compounds with improved therapeutic indices to the natural products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.